Defining Combination Prevention: Ongoing trials in sub-Saharan Africa
Stepping Up the Pace: VMMC accelerates in priority countries
As this graphic from AVAC Report 2012 illustrates, the pace of implementation of VMMC for HIV prevention has increased dramatically since 2010 in priority countries.
HIV Prevention Research: Defining moments since 2010
Published in AVAC Report 2011, this timeline shows the HIV prevention scientific breakthroughs from July 2010 to Nov 2011, including the CAPRISA 004, iPrEx and Partners PrEP trials.
Many Opportunities for HIV Prevention
To end AIDS, we need HIV prevention options that are highly effective before, during and after exposure or infection. This graphic from AVAC Report 2011 lists some of these tools.
AVAC Playbook 2012
AVAC Playbook 2012 includes AVAC’s analysis of what the top strategic goals should be on a global level, and particularly in hard-hit countries, over the year 2012. It also includes AVAC’s organizational priorities for contributing to these goals.
Invest Now to Save Lives and Funds
Published in AVAC Report 2011, this graphic was adapted from the paper authored by UNAIDS and others that advocated for a new “investment framework” for the AIDS response. It models changes in incidence and mortality if the world increases its investment in evidence-based AIDS programs–and what will happen if it doesn’t.
PxWire January-March 2011, Vol. 4, No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of PxWire takes inventory of the regulatory, trial-planning and scientific agenda-setting steps that are being taken with respect to recent positive trial results. It reviews ongoing and proposed next steps that have been triggered by the Thai prime-boost AIDS vaccine trial, the CAPRISA 004 microbicide trial and the iPrEx trial of once-daily TDF/FTC for pre-exposure prophylaxis.
2010 AVAC Report: Turning the Page (Thai translation)
The AVAC 2010 Report, Turning the Page, highlights that the biomedical prevention field is entering the next chapter of its development. The past year brought the first evidence, from the Thai Prime-Boost trial, that an AIDS vaccine could prevent HIV in humans, as well as significant preclinical findings around potent, HIV-specific neutralizing antibodies.
At the same time, two microbicide trials testing the candidate PRO 2000 yielded seemingly different, but ultimately disappointing results, and the field now prepares for the release of results from CAPRISA 004, the first ARV-based microbicide effectiveness trial.
Anticipating the Results of the Phase III AIDS Vaccine Trial in Thailand
A 2009 document discussing the RV144 vaccine trial in advance of efficacy data. It provides background information on the vaccine candidate and trial design, and explores potential scenarios for the results.
Finding Your Way: A guide to understanding ethical issues related to participation in clinical trials for preventive HIV vaccines
This guide is designed to help readers gain a better understanding of the ethical issues involved in developing a preventive HIV vaccine. While much of the guide is intended for a prospective clinical trial participant, it provides a basic introduction for anyone who wants to learn more about ethical issues and HIV vaccine development.